New combo aims to boost CAR T-Cell success in lymphoma patients
Disease control
Recruiting now
This early-stage study tests a combination of two drugs, CC-99282 and rituximab, in people with non-Hodgkin lymphoma whose cancer did not respond well to CAR T-cell therapy. The goal is to find a safe dose and see if the combo can help control the cancer. About 18 adults with cer…
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated May 11, 2026 20:39 UTC